Treatment for Multiple Myeloma

The cure rate of multiple myeloma is now over 90%.[10] There is an improvement of the quality of life after each treatment, but quality of life remains a challenge. This can lead to depression and anxiety. A patient's mood can be improved with psychopharmacological, psychotherapeutic, or supportive-cognitive behavior therapy. If the symptoms cannot be controlled, physical therapy can be helpful to reduce pain and fatigue.

It has been hypothesized that [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) may be a disease in which clonal expansion of a neoplastic cell may occur. The malignant cells in myeloma may develop into either malignant plasma cells or malignant myeloblastic cells. If the malignant plasma cells are large enough then they can grow into a myeloma tumor. This type of hypothesis could explain why there is a correlation between multiple myeloma and a history of immunodeficiency, such as a compromised immune system or premature aging. However, the myeloma cells do not have to be related; therefore, the malignant cells could be unrelated and they could develop in anyone who has a defect in a normal immune system.

2,037 people were diagnosed with multiple myeloma in the country. The incidence of people with multiple myeloma is low in countries such as Denmark and Japan.

There are a variety of symptoms of multiple myeloma. The presence of blood on urine in the urine, or blood in the sputum/trachea are other signs of multiple myeloma.\n

There are many different treatment options available for newly diagnosed and/or relapsed or refractory MM. All treatment options are discussed under each separate therapy section. It is only through careful analysis, evaluation and comparison of all treatment options that we hopefully can improve the quality of life in patients with MM.

Multiple myeloma affects as many as 20% of people with multiple myeloma and asymptomatic people. It usually results in bone marrow swelling with an increase in the production of large numbers of lymphocytes or platelets and typically occurs before the age of 50. This cancer has a poor prognostic character and is more difficult to treat than other types of myeloma.

The age has increased, in contrast to the previous 40 years. Although treatment is much better than in the past, the survival time has decreased as the average age increases. Therefore, the age deserves to be evaluated as a new prognosis stratifier parameter of survival time for multiple myeloma.

The findings demonstrate that multiple myeloma is a hereditary disease but the degree of heritability is low, indicating that other genetic markers must be involved.

Multiple myeloma was the 12th most common cancer in the United States in 2004. It affects about 20,000 people, of whom 19,150 died in 2004 in the United States of America. Most reported cases with multiple myeloma and plasma cell neoplasia in the United States were of the IgM subtype, which account for about half of all cases of multiple myeloma. In 2006, multiple myeloma made up about one-third of all malignant neoplasms (tumors of the body) and 20% of all malignant neoplasms in children and adolescents in the United States. In 2007, multiple myeloma surpassed breast cancer with respect to the number of new cancer cases.

Atypical multiple myeloma responds less to treatment than typical multiple myeloma when treated using current standards for treatment, though it often responds in response to treatment.

The present review discusses the recent (as of 2017) important medical advances about myeloma and its treatment. The developments in treatment of myeloma have included new chemotherapy regimens that require less [intense therapy.